Original Article

You have full text access to this OnlineOpen article

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength†

  1. Michael S Ominsky1,
  2. Fay Vlasseros2,
  3. Jacquelin Jolette2,
  4. Susan Y Smith2,
  5. Brian Stouch3,
  6. George Doellgast3,
  7. Jianhua Gong1,
  8. Yongming Gao1,
  9. Jin Cao1,
  10. Kevin Graham4,
  11. Barbara Tipton4,
  12. Jill Cai5,
  13. Rohini Deshpande5,
  14. Lei Zhou6,
  15. Michael D Hale6,
  16. Daniel J Lightwood7,
  17. Alistair J Henry7,
  18. Andrew G Popplewell7,
  19. Adrian R Moore7,
  20. Martyn K Robinson7,
  21. David L Lacey1,
  22. W Scott Simonet1,
  23. Chris Paszty1,*

Article first published online: 8 JAN 2010

DOI: 10.1002/jbmr.14

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 5, pages 948–959, May 2010

Additional Information

How to Cite

Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., Tipton, B., Cai, J., Deshpande, R., Zhou, L., Hale, M. D., Lightwood, D. J., Henry, A. J., Popplewell, A. G., Moore, A. R., Robinson, M. K., Lacey, D. L., Simonet, W. S. and Paszty, C. (2010), Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res, 25: 948–959. doi: 10.1002/jbmr.14

Author Information

  1. 1

    Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA, USA

  2. 2

    Bone Research, Charles River Laboratories, Preclinical Services Montreal, Senneville, Quebec, Canada

  3. 3

    Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, CA, USA

  4. 4

    Protein Sciences, Amgen, Inc., Thousand Oaks, CA, USA

  5. 5

    ATO Cell Sciences and Technology, Amgen, Inc., Thousand Oaks, CA, USA

  6. 6

    Biostatistics, Amgen, Inc., Thousand Oaks, CA, USA

  7. 7

    UCB-Celltech, Slough, United Kingdom

*Metabolic Disorders, M/S 14-1-B, One Amgen Center Drive, Amgen, Inc., Thousands Oaks, CA 91320-1799, USA.

  1. †

    Parts of the manuscript were presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research, in Philadelphia, PA, September 15–19, 2006

Publication History

  1. Issue published online: 30 APR 2010
  2. Article first published online: 8 JAN 2010
  3. Accepted manuscript online: 8 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 17 DEC 2009
  5. Manuscript Revised: 11 NOV 2009
  6. Manuscript Received: 24 SEP 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (691K)

References

  • 1
    Stepnick LS. The frequency of bone disease. In: MacGowanJA, NoonanAS, ElderkinAL, eds. Bone Health and Osteoporosis: A Report of Surgeon General. Washington, DC: USDHHS; 2004: 68–87.
  • 2
    Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab. 2007; 92: 747–753.
  • 3
    Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009; 5: 20–27.
  • 4
    Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003; 63: 192–197.
    Direct Link:
  • 5
    Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577–589.
  • 6
    Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537–543.
  • 7
    Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148: 2635–2643.
  • 8
    Piters E, Boudin E, Van Hul W. Wnt signaling: a win for bone. Arch Biochem Biophys. 2008; 473: 112–116.
  • 9
    Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860–869.
    Direct Link:
  • 10
    Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578–588.
    Direct Link:
  • 11
    Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009; 24: 1662–1671.
    Direct Link:
  • 12
    Ke HZ, Xiang JJ, Li X, Simonet WS, Paszty C, Li G. Inhibition of sclerostin by systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in mice and rats. Abstract and Oral presented at 55th Annual Orthopaedic Research Society Meeting February 22–25, 2009; Las Vegas, NV, 2009.
  • 13
    Brommage R. Perspectives on using nonhuman primates to understand the etiology and treatment of postmenopausal osteoporosis. J Musculoskelet Neuronal Interact. 2001; 1: 307–325.
  • 14
    Jerome CP, Peterson PE. Nonhuman primate models in skeletal research. Bone. 2001; 29: 1–6.
  • 15
    Smith SY, Jolette J, Turner CH. Skeletal health: primate model of postmenopausal osteoporosis. Am J Primatol. 2009; 71: 1–14.
    Direct Link:
  • 16
    Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone. 1993; 14: 595–608.
  • 17
    Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003; 88: 5212–5220.
  • 18
    Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1–84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res. 2007; 22: 260–273.
    Direct Link:
  • 19
    Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006; 21: 366–373.
    Direct Link:
  • 20
    Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 855–864.
    Direct Link:
  • 21
    Padhi D, Stouch B, Jang G, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res. 2007; 22: S1. S37.
View Full Article (HTML) Get PDF (691K)